Target | Example of drugs | Promising data? |
EGFR TK | Gefitinib Erlotinib | Yes, in patients with EGFR mutation. |
IGFR TK | AMG 479 BMS-754807 | None yet. Further trial results awaited. |
c-kit receptor TK | Imatinib | None yet. High study variability of c-kit mutation rate. |
c-MET receptor TK | AMG 102 | None yet. Trial results awaited. |
Farnesyltransferase | Tipifarnib | None yet. |
Src kinase | Dasatinib | None yet. |
mTOR | Everolimus Temsirolimus | Limited. Trial results awaited. |
PI3K | PF-4989216 | No trial data. |
PARP | Olaparib | Trial recently commenced. |
Hh | Vismodegib | No trial data. |
VEGF | Bevacizumab Cediranib Vandetanib Aflibercept | Some potential in advanced disease with bevacizumab. Aflibercept trial ongoing. |
MMPs | Marimastat Tanomastat | No benefit. |
Thalidomide | Therapeutic benefit in phase III trial but dose limited by significant toxicity [thrombotic events]. | |
PDGFR | Sorafenib Sunitinib | Sorafenib—none yet. Sunitinib-progression free survival, other trials ongoing. |
Bcl-2 | AT-101 ABT-737 Obatoclax | None yet. |
Proteosome | Bortezomib | None yet |
PLK1 | Bi2536 | None yet |
HDAC | Vorinostat Belinostat | Yes in animal studies, no clinical trial data yet. |
Multi-drug resistance proteins | Biricodar | None yet |
HER2 | Trastuzumab | No trial data. |
CD56 | BB-10901 | Early phase studies promising |
GD3 | BEC2 | None yet. |
P53 | Vaccine | May indicate chemotherapy responsiveness, but unclear if causative. |
CTLA-4 | Ipilimumab | Trial awaited. |